4D Molecular Therapeutics Inc
NASDAQ:FDMT
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Price:
26.38 USD
3.9%
Market Closed
Updated:
May 3, 2024
4D Molecular Therapeutics Inc
Operating Income
|
4D Molecular Therapeutics Inc
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
Operating Income
-$112.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is 4D Molecular Therapeutics Inc's Operating Income?
Operating Income
-112.9m
USD
-112.9m
USD
Based on the financial report for Dec 31, 2023, 4D Molecular Therapeutics Inc's Operating Income amounts to -112.9m USD.
What is 4D Molecular Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-61%
-61%
Over the last year, the Operating Income growth was -3%. The average annual Operating Income growth rates for 4D Molecular Therapeutics Inc have been -26% over the past three years , -61% over the past five years .
You don't have any saved screeners yet
